Literature DB >> 16430313

Comparable pharmacokinetics and pharmacodynamics of melagatran in Japanese and caucasian volunteers after oral administration of the direct thrombin inhibitor ximelagatran.

Linda C Wernevik1, Per Nyström, Magnus Andersson, Gillis Johnsson, Anders Bylock, Takashi Nakanishi, Ulf G Eriksson.   

Abstract

OBJECTIVES: Two studies were conducted to elucidate the pharmacokinetics and pharmacodynamics of melagatran after administration of the oral direct thrombin inhibitor ximelagatran to Caucasian and Japanese volunteers.
METHODS: In study 1, with a single-blind, parallel-group design, young Japanese and Caucasian male volunteers were randomised to receive four single escalating oral doses of ximelagatran (12, 24, 36 and 60mg on separate days; n = 27 per ethnic group) or placebo (n = 6 per ethnic group). In study 2, with an open-label design, elderly Japanese male volunteers (n = 12) received three single escalating oral doses of ximelagatran (12, 24 and 36mg on separate days).
RESULTS: Regardless of the ethnicity or age of the volunteers, ximelagatran given in single oral doses was rapidly absorbed and bioconverted to melagatran, and the melagatran area under the plasma concentration-time curve (AUC) and peak plasma concentration (C(max)) increased in proportion with the ximelagatran dose, with only small deviations from absolute linearity. Higher melagatran AUC and C(max) were observed in young Japanese volunteers compared with young Caucasian volunteers, and in elderly Japanese volunteers compared with young Japanese volunteers. These results appear to be attributed to weight- and age-related decreases in renal elimination of melagatran rather than to absorption of ximelagatran and formation of melagatran. The pattern of metabolites in plasma and urine was comparable between young Japanese and Caucasian volunteers, and between young and elderly Japanese volunteers. The melagatran plasma concentration-activated partial thromboplastin time (aPTT, an ex vivo coagulation time measurement used to demonstrate inhibition of thrombin) relationship did not differ significantly between young Japanese and Caucasian volunteers or between young and elderly Japanese volunteers.
CONCLUSIONS: Ethnicity does not affect the absorption of ximelagatran or the formation of melagatran or the melagatran plasma concentration-aPTT relationship. The elimination of melagatran is correlated with renal function.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16430313     DOI: 10.2165/00003088-200645010-00006

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  18 in total

Review 1.  Predictability of the effects of race or ethnicity on pharmacokinetics of drugs.

Authors:  J A Johnson
Journal:  Int J Clin Pharmacol Ther       Date:  2000-02       Impact factor: 1.366

Review 2.  Necessity and requirements of bridging studies and their present status in Japan.

Authors:  C Naito
Journal:  Int J Clin Pharmacol Ther       Date:  2000-02       Impact factor: 1.366

3.  No influence of ethnic origin on the pharmacokinetics and pharmacodynamics of melagatran following oral administration of ximelagatran, a novel oral direct thrombin inhibitor, to healthy male volunteers.

Authors:  Linda C Johansson; Magnus Andersson; Gunnar Fager; David Gustafsson; Ulf G Eriksson
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

4.  Determination of melagatran, a novel, direct thrombin inhibitor, in human plasma and urine by liquid chromatography-mass spectrometry.

Authors:  Marita Larsson; Ulrika Logren; Martin Ahnoff; Bo Lindmark; Peter Abrahamsson; Henrik Svennberg; Bengt-Arne Persson
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2002-01-05       Impact factor: 3.205

5.  Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients.

Authors:  Harumi Takahashi; Grant R Wilkinson; Yoseph Caraco; Mordechai Muszkat; Richard B Kim; Toshitaka Kashima; Sosuke Kimura; Hirotoshi Echizen
Journal:  Clin Pharmacol Ther       Date:  2003-03       Impact factor: 6.875

6.  Pharmacokinetics, pharmacodynamics and clinical effects of the oral direct thrombin inhibitor ximelagatran in acute treatment of patients with pulmonary embolism and deep vein thrombosis.

Authors:  Karin Wåhlander; Leif Lapidus; Carl-Gustav Olsson; Anneli Thuresson; Ulf G Eriksson; Göran Larson; Henry Eriksson
Journal:  Thromb Res       Date:  2002-08-15       Impact factor: 3.944

7.  Absorption, distribution, metabolism, and excretion of ximelagatran, an oral direct thrombin inhibitor, in rats, dogs, and humans.

Authors:  Ulf G Eriksson; Ulf Bredberg; Kurt-Jürgen Hoffmann; Anneli Thuresson; Margareth Gabrielsson; Hans Ericsson; Martin Ahnoff; Kristina Gislén; Gunnar Fager; David Gustafsson
Journal:  Drug Metab Dispos       Date:  2003-03       Impact factor: 3.922

8.  Ximelagatran, an oral direct thrombin inhibitor, has a low potential for cytochrome P450-mediated drug-drug interactions.

Authors:  Eva Bredberg; Tommy B Andersson; Lars Frison; Annelie Thuresson; Susanne Johansson; Maria Eriksson-Lepkowska; Marita Larsson; Ulf G Eriksson
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

9.  Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran.

Authors:  Sam Schulman; Karin Wåhlander; Torbjörn Lundström; Solveig Billing Clason; Henry Eriksson
Journal:  N Engl J Med       Date:  2003-10-30       Impact factor: 91.245

10.  Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement.

Authors:  Charles W Francis; Scott D Berkowitz; Philip C Comp; Jay R Lieberman; Jeffrey S Ginsberg; Guy Paiement; Gary R Peters; Anne W Roth; Jennifer McElhattan; Clifford W Colwell
Journal:  N Engl J Med       Date:  2003-10-30       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.